Advanced Search

 

Study ID Status Title Patient Level Data
217744/097 Completed Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine
217744/099 Completed A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age Study Listed on ClinicalStudyDataRequest.com
217744/100 Completed Assess safety & reactogenicity of DTPa-IPV/Hib vaccine admnd at 3 & 4 mths & DTPa-HBV-IPV/Hib vaccine admnd at 5 mths, followed by DTPa-IPV/Hib vaccine at 18 mths in infants who received hepatitisB vaccine at birth & at one month of age Study Listed on ClinicalStudyDataRequest.com
218352/054 Completed Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ influenza split vaccine FLUARIX™ administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination Study Listed on ClinicalStudyDataRequest.com
227855/001 Completed Phase I study in elderly population aged over 65 years in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccine or a Whole virus vaccine. For both immunogenicity and safety evaluations, the commercial inactivated split vaccine Fluarix will be used as reference Study Listed on ClinicalStudyDataRequest.com
240563/001 Completed A double blind, placebo controlled, dose rising study to assess safety, pharmacokinetics and effect on the early and late phase response to allergen challenge of SB-240563 in male patients with mild asthma
240563/006 Completed A multicenter, double-blind, randomized, placebo controlled, parallel group study to evaluate the safety and efficacy of Intravenous SB 240563 (250mg and 750mg) in patients with asthma.
240563/017 Completed A double-blind, placebo controlled, parallel group study to assess tolerability and pharmacokinetics of three 250 mg subcutaneous doses of SB-240563 in male and female patients with asthma
240563/035 Completed A double blind, placebo controlled, dose rising study to assess safety and pharmacokinetics of SB-240563 in male patients with mild asthma
240563/036 Completed A Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of 750 mg SB-240563 (Anti-IL-5) on Clinical Features, Cutaneous Late-Phase Reactions and Bronchial, Nasal, Skin, Bone Marrow and Blood Eosinophils in Male and Female Patients with Atopic Asthma
25000/541 Completed The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance Study Listed on ClinicalStudyDataRequest.com
25000/547 Completed An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 7 days for the Treatment of Bacterial Community-Acquired Pneumonia in adults. Study Listed on ClinicalStudyDataRequest.com
25000/555 Completed Evaluating the Impact of Amoxicillin/Clavulanate Potassium Therapy on Carriage of Susceptible and Resistant Streptococcus pneumoniae. Study Listed on ClinicalStudyDataRequest.com
25000/557 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults. Study Listed on ClinicalStudyDataRequest.com
25000/592 Completed An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults. Study Listed on ClinicalStudyDataRequest.com
25000/593 Completed A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
25000/600 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia. Study Listed on ClinicalStudyDataRequest.com
25000/601 Completed A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension. Study Listed on ClinicalStudyDataRequest.com
25000/611 Completed A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children. Study Listed on ClinicalStudyDataRequest.com
25000/620 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin. Study Listed on ClinicalStudyDataRequest.com
25000/627 Completed A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis Study Listed on ClinicalStudyDataRequest.com
25000/630 Completed A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis. Study Listed on ClinicalStudyDataRequest.com
25000/643 Completed A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A) Study Listed on ClinicalStudyDataRequest.com
25000/665 Completed An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension. Study Listed on ClinicalStudyDataRequest.com
257049/015 Completed Staggered study to evaluate safety and immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to a 0,1,3-month schedule in semi-immune children aged 6 to 11 years in Gambia, a malaria endemic region Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.